SE0104330D0 - Therapeutic agents - Google Patents
Therapeutic agentsInfo
- Publication number
- SE0104330D0 SE0104330D0 SE0104330A SE0104330A SE0104330D0 SE 0104330 D0 SE0104330 D0 SE 0104330D0 SE 0104330 A SE0104330 A SE 0104330A SE 0104330 A SE0104330 A SE 0104330A SE 0104330 D0 SE0104330 D0 SE 0104330D0
- Authority
- SE
- Sweden
- Prior art keywords
- sub
- sup
- group
- optionally substituted
- alkyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- -1 1-adamantylmethyl Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104330A SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
| PCT/GB2002/005742 WO2003051851A1 (fr) | 2001-12-19 | 2002-12-18 | Derives de 5, 6-diaryl-pyrazine-2-amide comme antagonistes de cb1 |
| IL16237702A IL162377A0 (en) | 2001-12-19 | 2002-12-18 | 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
| CNA028281535A CN1620438A (zh) | 2001-12-19 | 2002-12-18 | 用作cbi拮抗剂的5,6－二芳基－吡嗪－2－酰胺衍生物 |
| NZ533275A NZ533275A (en) | 2001-12-19 | 2002-12-18 | 5, 6-Diaryl-pyrazine-2-amide derivatives as CB1 antagonists |
| CA002469786A CA2469786A1 (fr) | 2001-12-19 | 2002-12-18 | Derives de 5, 6-diaryl-pyrazine-2-amide comme antagonistes de cb1 |
| EP02788143A EP1458690B1 (fr) | 2001-12-19 | 2002-12-18 | Derives de 5, 6-diaryl-pyrazine-2-amide comme antagonistes de cb1 |
| AT02788143T ATE354570T1 (de) | 2001-12-19 | 2002-12-18 | 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten |
| MXPA04005990A MXPA04005990A (es) | 2001-12-19 | 2002-12-18 | Derivados de 5,6-diaril-pirazina-2-amida como antagonistas de cb1. |
| RU2004116916/04A RU2004116916A (ru) | 2001-12-19 | 2002-12-18 | Производные 5,6-биарил-пиразин-2-амида в качестве антагонистов cb1 |
| AU2002352425A AU2002352425A1 (en) | 2001-12-19 | 2002-12-18 | 5,6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists |
| PL02369731A PL369731A1 (en) | 2001-12-19 | 2002-12-18 | 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
| BR0214989-3A BR0214989A (pt) | 2001-12-19 | 2002-12-18 | Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças, e, processo para a preparação de um composto |
| ES02788143T ES2280599T3 (es) | 2001-12-19 | 2002-12-18 | Derivados de 5,6-diaril-pirazin-2-amida como antagonistas de cb1. |
| US10/499,054 US7342019B2 (en) | 2001-12-19 | 2002-12-18 | 5, 6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists |
| DE60218340T DE60218340T2 (de) | 2001-12-19 | 2002-12-18 | 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten |
| KR10-2004-7009589A KR20040068286A (ko) | 2001-12-19 | 2002-12-18 | Ｃｂ１ 길항물질로서의 5,6-디아릴-피라진-2-아미드 유도체 |
| JP2003552736A JP2005517655A (ja) | 2001-12-19 | 2002-12-18 | Ｃｂ１アンタゴニストとしての５，６−ジアリール−ピラジン−２−アミド誘導体 |
| HU0402026A HUP0402026A3 (en) | 2001-12-19 | 2002-12-18 | 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them |
| TW091136671A TW200410694A (en) | 2001-12-19 | 2002-12-19 | Therapeutic agents |
| ARP020105001A AR038044A1 (es) | 2001-12-19 | 2002-12-19 | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. |
| IS7314A IS7314A (is) | 2001-12-19 | 2004-06-16 | 5,6-díarýl-pýrasín-2-amíðafleiður sem cb1 mótlyf |
| ZA200404805A ZA200404805B (en) | 2001-12-19 | 2004-06-17 | 5,6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists. |
| CO04065292A CO5590917A2 (es) | 2001-12-19 | 2004-07-09 | Derivados de 5,6-diaril-pirazina-2-amida como antagonistas cb1 |
| NO20043022A NO20043022L (no) | 2001-12-19 | 2004-07-15 | 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104330A SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0104330D0 true SE0104330D0 (sv) | 2001-12-19 |
Family
ID=20286429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0104330A SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7342019B2 (fr) |
| EP (1) | EP1458690B1 (fr) |
| JP (1) | JP2005517655A (fr) |
| KR (1) | KR20040068286A (fr) |
| CN (1) | CN1620438A (fr) |
| AR (1) | AR038044A1 (fr) |
| AT (1) | ATE354570T1 (fr) |
| AU (1) | AU2002352425A1 (fr) |
| BR (1) | BR0214989A (fr) |
| CA (1) | CA2469786A1 (fr) |
| CO (1) | CO5590917A2 (fr) |
| DE (1) | DE60218340T2 (fr) |
| ES (1) | ES2280599T3 (fr) |
| HU (1) | HUP0402026A3 (fr) |
| IL (1) | IL162377A0 (fr) |
| IS (1) | IS7314A (fr) |
| MX (1) | MXPA04005990A (fr) |
| NO (1) | NO20043022L (fr) |
| NZ (1) | NZ533275A (fr) |
| PL (1) | PL369731A1 (fr) |
| RU (1) | RU2004116916A (fr) |
| SE (1) | SE0104330D0 (fr) |
| TW (1) | TW200410694A (fr) |
| WO (1) | WO2003051851A1 (fr) |
| ZA (1) | ZA200404805B (fr) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
| WO2004029204A2 (fr) | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Pyrimidines substituees |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0302673D0 (en) | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314049D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| WO2004111033A1 (fr) * | 2003-06-18 | 2004-12-23 | Astrazeneca Ab | Agents therapeutiques |
| GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| EP1644335A4 (fr) | 2003-07-11 | 2008-06-04 | Bristol Myers Squibb Co | Derives de tetrahydroquinoleine constituant des modulateurs des recepteurs des cannabinoides |
| US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| CA2537535A1 (fr) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Nouvelles utilisations medicales d'antagonistes selectifs du recepteur cb<sb>1</sb> |
| US7320805B2 (en) * | 2003-10-01 | 2008-01-22 | Institut National De La Sante Et De La Recherche Medicale | CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver |
| EP1670460B1 (fr) | 2003-10-10 | 2014-11-26 | Bristol-Myers Squibb Company | Derives de pyrazole utilises comme modulateurs du recepteur de cannabinoide |
| TW200528102A (en) * | 2003-10-24 | 2005-09-01 | Solvay Pharm Gmbh | Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| RU2006117637A (ru) * | 2003-10-24 | 2007-12-10 | Зольвай Фармасьютиклз Гмбх (De) | Комбинированное лечение ожирения с применением избирательных антагонистов cb1-рецептора и ингибиторов липаз |
| GB0327331D0 (en) * | 2003-11-25 | 2003-12-31 | Astrazeneca Ab | Therapeutic agents |
| EP1734963A4 (fr) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques |
| TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| AU2005298692A1 (en) | 2004-10-25 | 2006-05-04 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions |
| RU2404164C2 (ru) | 2005-04-06 | 2010-11-20 | Ф.Хоффманн-Ля Рош Аг | Производные пиридин-3-карбоксамида в качестве обратных агонистов св1 |
| JP2008536950A (ja) * | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのｃｂ１拮抗薬 |
| JP2008545009A (ja) | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Ｇｐｃｒアゴニスト |
| US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| BRPI0717845A2 (pt) * | 2006-10-04 | 2015-06-16 | Hoffmann La Roche | Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| PE20081659A1 (es) | 2007-01-04 | 2008-10-24 | Prosidion Ltd | Agonistas de gpcr |
| CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| ATE523507T1 (de) | 2007-01-04 | 2011-09-15 | Prosidion Ltd | Piperidin-gpcr-agonisten |
| EA016507B1 (ru) | 2007-01-04 | 2012-05-30 | Прозидион Лимитед | Пиперидиновые агонисты gpcr |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| WO2010079241A1 (fr) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
| WO2022031946A1 (fr) | 2020-08-06 | 2022-02-10 | Chdi Foundation, Inc. | Composés hétérobiaryles et agents d'imagerie pour l'imagerie de la protéine huntingtine |
| AR131658A1 (es) * | 2023-01-30 | 2025-04-16 | Eurofarma Laboratorios S A | Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y sus kits |
| AR131690A1 (es) * | 2023-01-30 | 2025-04-23 | Eurofarma Laboratorios S A | COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH458361A (de) * | 1965-01-15 | 1968-06-30 | Eprova Ag | Verfahren zur Herstellung von Pyrazincarbonsäuren |
| JPS5322529A (en) * | 1976-08-13 | 1978-03-02 | Nippon Soda Co Ltd | Dihydropyrazine derivative and its preparation |
| EP0397859A4 (en) * | 1987-11-12 | 1990-12-19 | Terumo Kabushiki Kaisha | Pyrazine derivatives and medicinal preparation containing same |
| JPH06501926A (ja) * | 1990-08-06 | 1994-03-03 | 藤沢薬品工業株式会社 | 複素環式化合物 |
| FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
-
2001
- 2001-12-19 SE SE0104330A patent/SE0104330D0/xx unknown
-
2002
- 2002-12-18 MX MXPA04005990A patent/MXPA04005990A/es unknown
- 2002-12-18 BR BR0214989-3A patent/BR0214989A/pt not_active IP Right Cessation
- 2002-12-18 CA CA002469786A patent/CA2469786A1/fr not_active Abandoned
- 2002-12-18 NZ NZ533275A patent/NZ533275A/en unknown
- 2002-12-18 AU AU2002352425A patent/AU2002352425A1/en not_active Abandoned
- 2002-12-18 PL PL02369731A patent/PL369731A1/xx not_active Application Discontinuation
- 2002-12-18 AT AT02788143T patent/ATE354570T1/de not_active IP Right Cessation
- 2002-12-18 WO PCT/GB2002/005742 patent/WO2003051851A1/fr not_active Ceased
- 2002-12-18 IL IL16237702A patent/IL162377A0/xx unknown
- 2002-12-18 JP JP2003552736A patent/JP2005517655A/ja active Pending
- 2002-12-18 CN CNA028281535A patent/CN1620438A/zh active Pending
- 2002-12-18 RU RU2004116916/04A patent/RU2004116916A/ru not_active Application Discontinuation
- 2002-12-18 ES ES02788143T patent/ES2280599T3/es not_active Expired - Lifetime
- 2002-12-18 DE DE60218340T patent/DE60218340T2/de not_active Expired - Fee Related
- 2002-12-18 US US10/499,054 patent/US7342019B2/en not_active Expired - Fee Related
- 2002-12-18 KR KR10-2004-7009589A patent/KR20040068286A/ko not_active Withdrawn
- 2002-12-18 EP EP02788143A patent/EP1458690B1/fr not_active Expired - Lifetime
- 2002-12-18 HU HU0402026A patent/HUP0402026A3/hu unknown
- 2002-12-19 TW TW091136671A patent/TW200410694A/zh unknown
- 2002-12-19 AR ARP020105001A patent/AR038044A1/es not_active Application Discontinuation
-
2004
- 2004-06-16 IS IS7314A patent/IS7314A/is unknown
- 2004-06-17 ZA ZA200404805A patent/ZA200404805B/en unknown
- 2004-07-09 CO CO04065292A patent/CO5590917A2/es not_active Application Discontinuation
- 2004-07-15 NO NO20043022A patent/NO20043022L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20050032808A1 (en) | 2005-02-10 |
| HUP0402026A3 (en) | 2005-08-29 |
| BR0214989A (pt) | 2004-12-14 |
| NO20043022L (no) | 2004-07-15 |
| AU2002352425A1 (en) | 2003-06-30 |
| AR038044A1 (es) | 2004-12-22 |
| EP1458690A1 (fr) | 2004-09-22 |
| PL369731A1 (en) | 2005-05-02 |
| JP2005517655A (ja) | 2005-06-16 |
| NZ533275A (en) | 2006-02-24 |
| KR20040068286A (ko) | 2004-07-30 |
| MXPA04005990A (es) | 2004-09-27 |
| RU2004116916A (ru) | 2005-11-10 |
| IS7314A (is) | 2004-06-16 |
| ES2280599T3 (es) | 2007-09-16 |
| CN1620438A (zh) | 2005-05-25 |
| WO2003051851A1 (fr) | 2003-06-26 |
| HUP0402026A2 (hu) | 2005-02-28 |
| DE60218340T2 (de) | 2007-11-29 |
| CO5590917A2 (es) | 2005-12-30 |
| TW200410694A (en) | 2004-07-01 |
| US7342019B2 (en) | 2008-03-11 |
| DE60218340D1 (de) | 2007-04-05 |
| ATE354570T1 (de) | 2007-03-15 |
| EP1458690B1 (fr) | 2007-02-21 |
| CA2469786A1 (fr) | 2003-06-26 |
| ZA200404805B (en) | 2005-08-15 |
| IL162377A0 (en) | 2005-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE0104330D0 (sv) | Therapeutic agents | |
| TW200503692A (en) | Therapeutic agents | |
| TW200507839A (en) | Therapeutic agents | |
| WO2004020431A3 (fr) | Nouveaux dérivées de benzoimidazole utilisés en tant qu'agents antiprolifératifs | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| NO20055421L (no) | Kinolinderivater som fosfodiestrase-inhibitorer | |
| CA2272291A1 (fr) | Quino- et quinazolines antagonistes crf | |
| AU7517400A (en) | N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent | |
| PT842923E (pt) | Derivados do pirrolo e composicoes medicinais | |
| AP9901578A0 (en) | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents. | |
| PL353646A1 (en) | Aminobenzophenones as inhibitors of il-1beta and tnf-alpha | |
| AU8799201A (en) | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | |
| EA200501703A1 (ru) | Применение производных азетидинкарбоксамида в терапии | |
| SI1210320T1 (en) | Aminobenzophenones as inhibitors of il-1beta and tnf-alpha | |
| AR044830A1 (es) | Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester | |
| IL148875A0 (en) | Sulfonyl hydrazide derivatives, their preparation and pharmaceutical compositions containing them | |
| NO20064238L (no) | Imidazolinderivater med CB1 agonistlsk aktivitet | |
| CA2345069A1 (fr) | Derives de 2-phenylpyran-4-one | |
| DE69512816D1 (de) | Oxopyridylchinoxalin Derivate | |
| DE69828197D1 (de) | Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut | |
| ATE397609T1 (de) | Corticotropinfreisetzungsfaktor antagonisten | |
| EP0183369A3 (fr) | Dérivés de dihydroisoquinoléine, procédé pour leur préparation et compositions pharmaceutiques les contenant | |
| GB0327331D0 (en) | Therapeutic agents | |
| WO2005007630A3 (fr) | Composes azapolycycliques fusionnes avec aryle | |
| ATE409698T1 (de) | 1,2,4-triazolderivat, verfahren zu dessen herstellung, und dieses enthaltende pharmazeutische zusammensetzung |